Linking SOX10 to a slow-growth resistance phenotype.
Slow-cycling BRAF melanoma cells are notoriously resistant to standard chemotherapy or targeted therapy but the underlying mechanism remains elusive. Now a new study unlocks this mystery and offers novel insights into developing more effective therapeutic interventions.
1] Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA [2] Melanoma Research Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Gao
G
Zhang
1] Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA [2] Melanoma Research Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Meenhard
M
Herlyn
D000970:Antineoplastic Agents / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D051739:Microphthalmia-Associated Transcription Factor / Q000378:metabolism; D009154:Mutation; D010641:Phenotype; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000378:metabolism; D055757:SOXE Transcription Factors / Q000378:metabolism*; D013449:Sulfonamides / Q000627:therapeutic use; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D051739:Microphthalmia-Associated Transcription Factor; D047428:Protein Kinase Inhibitors; D034741:RNA, Small Interfering; C527923:SOX10 protein, human; D055757:SOXE Transcription Factors; D013449:Sulfonamides; D000077484:Vemurafenib; C512478:EGFR protein, human; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf